echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Junshi Bio: JS103 injection received the notification of acceptance of drug clinical trial application

    Junshi Bio: JS103 injection received the notification of acceptance of drug clinical trial application

    • Last Update: 2021-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    On March 5, Junshi Bio announced that the company received the "Notice of Acceptance" approved and issued by the National Medical Products Administration, and the clinical trial application for JS103 injection was accepted

    .
    JS103 is a pegylated uricase derivative independently developed by the company, which is mainly used for the treatment of hyperuricemia with or without gout

    .


    JS103 is a pegylated uricase derivative independently developed by the company.
    It is mainly used for the treatment of hyperuricemia with or without gout.
    It can catalyze the oxidation of uric acid into allantoin, which has a significantly higher solubility than uric acid.
    Reduce the effect of blood uric acid

    .
    Hyperuricemia is a metabolic syndrome in which excessive uric acid is produced due to the disorder of purine metabolism or the excretion of uric acid is blocked, causing the uric acid in the blood to exceed the critical value

    .
    Gout is a crystal-associated joint disease caused by monosodium urate deposition and is directly related to hyperuricemia

    .
    According to "China High Urine, the board of directors and all directors guarantee that the content of this announcement does not contain any false records, misleading statements or major omissions, and bear legal responsibility for the authenticity, accuracy and completeness of its content

    .
    The Guidelines for the Diagnosis and Treatment of Acidemia and Gout (2019) show that the overall prevalence of hyperuricemia in China is 13.
    3%, and that of gout is 1.
    1%.
    Gout and related diseases caused by hyperuricemia are one of the chronic diseases with high incidence in China.
    Therefore, the development of JS103 is expected to bring more treatment options to patients

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.